Key Drivers
- Profitability Strength
- Strong Cash Flow
- Premium Valuation
AIAI Summary
A has re-rated from a defensive lab-tools name into a higher-quality compounder with improving margins, strong FCF, and new diagnostics/regulatory tailwinds, but at ~30x earnings the stock now needs continued execution—especially in China and cash conversion—to justify further upside rather than risk multiple compression.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Profitability Strength
- •Strong Cash Flow
- •Premium Valuation
A is a highly profitable, cash-generative business with improving liquidity and leverage, but its premium valuation and intangibles-heavy balance sheet limit downside protection.
Price Behavior
Key Price Behavior Insights:
- •Higher lows
- •Support holding
- •Near resistance
Over the last month, A has trended higher with a series of higher lows and support building around $140-$141, but it is now stretched near $149.5 and vulnerable to a short-term pause unless it breaks resistance.
Roughly 13% gain over the period has left the stock short-term stretched near resistance
Sentiment & News
Key News Insights:
- •EU certification
- •PFAS research
- •Investor interest
Agilent's latest updates point to steady momentum in diagnostics and research, led by EU certification for its PD-L1 companion diagnostic, a strategic X-ray tech investment, PFAS research support, and rising investor attention ahead of Q3 results.
These developments reinforce Agilent's execution across diagnostics and applied research, while keeping the stock on investors' radar ahead of earnings
Similar Companies in Healthcare
Other companies in the same sector with AI ratings